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Abstract
Introduction: Hydroxyethyl starch (HES) is a commonly used colloid in critically ill patients. However, its safety has
been questioned in recent studies and meta-analyses.
Methods: We re-evaluated prospective randomised controlled trials (RCT) from four meta-analyses published in
2013 that compared the effect of HES with crystalloids in critically ill patients, focusing on the adherence to
‘presumably correct indication’. Regarding the definition of ‘presumably correct indication’, studies were checked
for the following six criteria (maximum six points): short time interval from shock to randomisation (<6 h),
restricted use for initial volume resuscitation, use of any consistent algorithm for haemodynamic stabilisation,
reproducible indicators of hypovolaemia, maximum dose of HES, and exclusion of patients with pre-existing renal
failure or renal replacement therapy.
Results: Duration of fluid administration ranged from 90 min up to a maximum of 90 days. Four studies considered
follow-up until 90-day mortality, three studies 28-/30-day mortality, whereas four studies reported only early mortality.
Included studies showed a large heterogeneity of the indication score ranging between 1 and 4 points with a median
(25%; 75% quartile) of 4 (2; 4).
Conclusions: The most important question, whether or not HES may be harmful when it is limited to immediate
haemodynamic stabilisation, cannot be answered yet in the absence of any study sufficiently addressing this question.
In order to overcome the limitations of most of the previous studies, we now suggest an algorithm emphasising the
strict indication of HES. Additionally, we give a list of suggestions that should be adequately considered in any
prospective RCT in the field of acute volume resuscitation in critically ill patients.
Introduction
Several previous trials [1-3] question the safety of hydro-
xyethyl starch (HES) solutions compared to crystalloid
solutions in critically ill patients, whereas other trials did
not suggest any adverse effects [4-7]. These diverging
results may be the consequence of multiple factors includ-
ing different patient populations and types of HES (particu-
larly in terms of molecular weight, substitution coefficient,
raw material, and concentration [8,9]). However, we believe
that one of the most important factors has not yet been
explored in detail. In contrast to current practice and to
package inserts, colloids should primarily be supposed to
replace intravascular volume loss and depletion and should
be administered under strict conditions.
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In previous trials [1-3], however, fluid therapy, including
administration of HES, was often neither standardised nor
limited regarding dose, time frame or selection of patients
at risk. It is even more inscrutable as those studies recom-
mending not using colloids in general on the intensive
care unit (ICU) had stabilised their patients with colloids
before randomisation [1-3].
One of the next fundamental problems in the field of
fluid therapy in critically ill patients is the divergence and
impreciseness of terms specifying fluid therapy at all during
the last decades. In this respect, we choose to use the term
‘fluid administration’ for maintenance of fluid balance
(a condition where crystalloids should be preferred) and
the term ‘acute volume resuscitation’ for the treatment of
acute volume depletion (a condition where colloids might
be preferred).
The European Medicines Agency’s (EMA’s) Pharma-
covigilance Risk Assessment Committee (PRAC) con-
cluded on 14 June 2013, that the available evidence
suggests that the benefits of solutions containing HES
no longer outweigh their risks and therefore recom-
mended that the marketing authorisations for these
medicines be suspended. Unfortunately, the PRAC has
extrapolated these results to all patients irrespective of
underlying conditions although there are still ongoing
controversies on this subject due to unpublished data
(CRYSTAL [10], BaSES [7], RAFTinG [11] and so on),
and the use of HES in non-septic patients (for example
intraoperative use) has not been addressed in the afore-
mentioned studies, raising concerns about the safety
of HES.
In this review, we discuss recent prospective rando-
mised controlled trials (RCTs) comparing HES with crys-
talloids for fluid therapy in critically ill patients focusing
on the adherence to a ‘presumably correct indication’,
and give suggestions for the design of future prospective
RCTs.
Material and methods
In a first step, we screened the four recent meta-analyses
published in 2013 [12-15] including RCTs with critically ill
patients following sepsis, trauma, burns or any other dis-
ease hospitalised in an ICU. The intervention group
received any type of HES. Control patients received 0.9%
saline, Ringer’s acetate, or Ringer’s lactate. We excluded
trials that exclusively compared HES with either other syn-
thetic colloid or albumin that may potentially induce
equally harmful effect and thereby mask any effects of
HES. We prospectively decided to include only studies
published in English.
In a second step, we analysed studies on the adherence
to ‘presumably correct indication’ using both the four
meta-analyses [12-15] and original published manuscripts.
Then, we defined the following six criteria and generated a
six-point score:
1. Did the authors randomise patients within a maxi-
mum of 6 h after the first sign of shock? This arbitrary
time period was chosen based on Rivers et al. [16] and
the Surviving Sepsis Campaign Guidelines [17].
2. Did the authors restrict HES for initial volume
resuscitation? (We acknowledge that this issue
is in conflict with its licensing and marketing
authorisation.)
3. Did the authors use any consistent algorithm for
haemodynamic stabilisation?
4. Do baseline data enable identification of reproducible
indicators of hypovolaemia, haemodynamic instability
or increased lactate?
5. Did the authors adhere to the summary of product
characteristics, particularly to maximal dose of HES
per day (for example, 6% HES 130/0.4 <50 mL/kg; 6%
HES 200/0.5 <33 mL/kg; 10% HES 200/0.5 <20 mL/
kg)? (Details of product characteristics have recently
been summarised [9]).
6. Did the authors adhere to safety issues of product
characteristics, particularly to the contraindication for
patients with pre-existing renal failure or renal replace-
ment therapy (RRT)?
Results and discussion
Detailed descriptions of the 11 included studies
[1-7,18-21] are given in Table S1 in Additional file 1.
Four studies considered follow-up until 90-day mortality
[1-3,18], three studies 28-/30-day mortality [6,7,19],
whereas four studies reported only early mortality (24-h,
ICU, or hospital mortality) [4,5,20,21].
The type of HES studied was 6% Voluven 130/0.40 (Fre-
senius Kabi, Bad Homburg, Germany) [2,4-7,18], 6% Elo-
Haes 200/0.6 (Fresenius Kabi, Bad Homburg, Germany)
[21], 6% Tetraspan 130/0.42 (B. Braun Melsungen, Melsun-
gen, Germany) [3], 6% Hemohes 200/0.45 to 0.55 (B. Braun
Melsungen, Melsungen, Germany) [20], 10% Hemohes
200/0.45 to 0.55 (B. Braun Melsungen, Melsungen,
Germany) [1], and 10% pentastarch 200 to 300/0.5 [19].
Duration of fluid administration ranged from 90 min [6],
24 h [5,21], 96 h [1,18] up to a maximum of 90 days [2,3].
The ratio of the amounts of HES and crystalloids ranged
between 1:1 [3,4,6,19,21], 1:1.1 [7], 1:1.2 [2,18,20], 1:1.3 [1],
up to a maximum of 1:2.4 [5].
Results from analysing the likelihood of the adherence to
a ‘presumably correct indication’ are summarised in
Table 1 and are shown in detail in Table S2 in Additional
file 2. Studies showed a large variability of the score ran-
ging between 1 and 4 points with a median (25%; 75%
quartile) of 4 (2; 4).
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We address a highly controversially discussed issue -
whether or not HES might be safe in specified subgroups
of patients if correct indication is considered?
Four recent systematic reviews [12-15] have been pub-
lished within the last couple of months focusing on HES
and fluid therapy in critically ill patients. The main find-
ings of these meta-analyses were that patients assigned to
HES may have a statistically significant increased risk of
mortality and increased risk of getting RRT. In detail, HES
resulted in a significantly increased risk of mortality and
receiving RRT in the 6S trial [3], a significantly increased
risk of renal failure in the VISEP trial [1], whereas risk for
mortality and renal failure did not differ in the CHEST
trial [2] referring to the adjusted analysis published in the
supplement, respectively.
Interestingly, these studies have, however, been exten-
sively criticised on the basis of late enrolment of patients,
inadequate evidence of hypovolaemia and the need for
volume resuscitation, as well as the lack of properly tar-
geted endpoints for resuscitation [22-24]. More impor-
tantly, almost all of the previous meta-analyses [12-15]
analysed methodological quality criteria and risk of bias,
but none of these reviews considered the large heterogene-
ity regarding clinical conditions and the flaws in study
design of the included trials.
We believe that the design of these trials underestimated
the importance of having haemodynamic endpoints and
neglected the understanding of how fluids should be
administered. Their conclusions that HES should be
avoided will probably lead to inappropriate administration
of large amounts of crystalloids, albumin and/or red blood
cells in the future.
From a physiological point of view, acute volume
resuscitation with colloids should result in less amounts
of fluids needed for haemodynamic stabilisation com-
pared to crystalloids [25]. Supporting this hypothesis,
several studies showed a ratio of the amounts of HES
and crystalloids that was higher than 1:1 [1,2,5,18,20]. In
the 6S trial [3] contrarily, the cumulative amount of
study drug did not differ between the HES and crystalloid
group during the first 3 days. Also, the daily amount of
study drug did not decrease over time in this trial,
although the amount of fluids needed for acute volume
resuscitation is theoretically supposed to decrease day
by day, as septic patients can typically be stabilised
within 48 to 72 h. Taken together, this strategy of
fluid therapy may be associated with an increased risk
of fluid overloading that may have contributed to the
observed higher rate of patients getting RRT and mor-
tality, at least in part [3].
Table 1 Probability of ‘presumably correct indication’ (six-point score)
Criteria for ‘presumably correct indication’
Patients
(total, n)
Score
(Y, n)
Time
interval
(start <6
h)
Restricted to acute
volume resuscitation
(Duration)
Algorithm for
fluid
administration
Haemodynamic
instability at
randomisation
Maximum
dose
Exclusion of
renal failure/
RRT
Du, 2011 [4] 42 1 No No Y No No No
Perner, 2012 (6S) [3] 804 1 No No No No Y Nob
Brunkhorst, 2008
(VISEP) [1]a
537 2 No No Y No Noc Yd
Myburgh, 2012
(CHEST) [2]
6,742 2 No No No No Y Y
van der Heijden,
2009 [20]a
48 3 No Y Y No Y n.a.
Dubin, 2010 [5] 20 4 Y No Y Y Ye n.a.
Guidet, 2012
(CRYSTMAS) [18]
174 4 Y No Y Yf Y Nog
James, 2011
(FIRST) [6]
109 4 Y No Y Y No Y
McIntyre, 2008
(FINESS) [19]a
40 4 Y No Y Y Noh Yi
Siegemund, 2013
(BaSES) [7]
241 4 Y No Y n.a. Y Y
Vlachou, 2010 [21]a 26 4 Y No Y No Y Y
aMolecular weight was 200 kDa, which is known as an independent risk factor for mortality; bacute kidney injury, defined as renal SOFA score of ≥2, creatinine
>1.9 mg/dL or urine output<500 mL/d, was present in up to 36% of patients; cinconsistencies between study protocol specifications and published baseline data
in up to 38% of patients; drenal dysfunction (urine output ≤0.5 mL/kg/h for 1 h and/or serum creatinine >2 times normal ranges) was present in up to 10.9% of
patients; edata for body weight are not provided, fpersonal communication; ginconsistencies between study protocol specifications and published baseline data
in up to 68% of patients; hafter 12 h, the quantity and type of fluid administered were at the discretion of the treating physician; ilimited to chronic renal failure
with renal replacement therapy. Y = Yes; n.a.= not assessed; RRT, renal replacement therapy.
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Moreover, banishing colloids from clinical routine and
preferentially using non-colloids might likely result in
higher amounts of crystalloids, albumin and red blood
cells needed to reach haemodynamic endpoints. This new
paradigm might open the ‘floodgates’ for the use of even
more amounts of crystalloid fluids potentially increasing
the incidence of fluid overload and interstitial oedema.
Recent observational studies [26-28] suggested that posi-
tive fluid balance is associated with increased morbidity
and mortality. Obviously sicker patients who never reverse
their capillary permeability deficit have a positive fluid bal-
ance leading to an increased risk of mortality. Neverthe-
less, using multivariate analysis, positive fluid balance
remained an independent risk factor for 28-day mortality
after adjustment for age, gender, diabetes, hypertension,
diuretic use, non-renal sequential organ failure assessment
(SOFA) and sepsis [26]. That is why the results of these
studies should be critically re-evaluated, and why any
planned prospective RCTs in the field of volume resuscita-
tion in critically ill patient should adequately consider the
suggestions outlined in this paper.
General limitations of the included trials
We are concerned that major limitations may have biased
previous study results, and that they are not adequately
considered within the ongoing discussion. In this respect,
we would like to highlight a few very important issues:
1. Fluid therapy before inclusion of patients
Up to 52% [3] and 59% [1] of all study patients had
already received large amounts of colloids for acute
haemodynamic stabilisation before formal randomisa-
tion. In this respect, a substantiate characterisation of
HES-specific effects is very difficult, and late randomi-
sation of patients may lead to inclusion of patients
who have well exceeded predefined haemodynamic
targets. It makes the whole story even more critical
as those studies recommending not using colloids in
general in the ICU had stabilised their patients with
colloids initially before randomisation [1-3].
2. Prolonged administration of HES
In some studies, HES was allowed to be administered
up to a maximum of 90 days [6,7]. However, pro-
longed administration of HES after the initial phase of
haemodynamic instability increases the risk of giving
HES to non-hypovolaemic patients [5-7,13,17]. Thus,
persistent use with presumably weak indication has no
beneficial effect or may even be harmful.
3. No control of other risk factors for mortality/renal
failure (for example, blood transfusion)
More patients in the starch groups received packed
red cells, although the transfusion algorithm was not
standardised. A high priority should be assigned to
this task, as transfusion of red cells is independently
associated with higher mortality among patients in the
intensive care unit.
4. No protocol for renal replacement therapy (RRT)
None of the trials used any protocol for RRT. How-
ever, this is of great importance, since mode, timing,
dose and other device settings may have an impact on
its efficacy and patient outcome [29-31]. As long as
‘need for RRT’ is a study endpoint, indication for RRT
should clearly be specified.
5. Study protocol violations
Although exclusion criteria and maximum dose of
HES were specified in the study protocols, conflicts
between study protocol specifications and published
baseline data were found in a few studies [1,3,18].
Future perspectives - our ‘eight suggestions’
HES is a potent drug with presumably beneficial charac-
teristics, but also known dose-dependent adverse effects.
Importantly, most of the early goal-directed approaches
suggesting improved outcome after major surgery were
based on colloid application [32-34]. To ensure a presum-
ably positive benefit/risk ratio, indication of HES should
be strictly limited to the restoration of intravascular
volume in hypovolaemic patients (acute volume resuscita-
tion). Otherwise, infusion of HES and any other fluid
would result in hypervolaemia, thereby shedding the
endothelial glycocalyx and aggravating the capillary leak
syndrome [35], especially in septic patients. In this respect,
randomisation of patients up to 24 h after diagnosis of
severe sepsis may lead to the inclusion of patients who
have exceeded predefined haemodynamic targets, since in
the starch groups of the VISEP [1] and 6S trials [3], the
median values were: central venous oxygen saturation,
75% and 75%; and serum lactate level, 2.2 and 2.0 mmol/L,
respectively. This might explain why 411 out of the 798
patients included in the 6S trial (52%), and 315 out of the
537 patients included in the VISEP trial (59%), had already
received colloids before randomisation, irrespective of
group assignment and the risk of renal failure.
In accordance to the current surviving sepsis campaign
bundles, initiation of acute volume resuscitation and vaso-
pressor therapy should be completed within 3 to 6 h [17].
1. We suggest that initiation of HES infusion should
be limited to a short time frame after onset of shock
if acute volume resuscitation has started (for example,
within a maximum of, in general, 6 h). (We acknowl-
edge that no evidence-based clinical data exists that
supports the arbitrary selection of this time period.)
Duration of fluid administration ranged from 90 min [6],
24 h [5,21], 96 h [1,18], up to a maximum of 90 days [2,3].
Only one trial exclusively restricted the use of HES to
initial volume resuscitation for acute haemodynamic stabi-
lisation [20]. In this respect, no conclusion as to the type
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of intravenous fluid to use during this sensitive period can
be reached yet. Prolonged administration of HES after the
initial phase of haemodynamic instability and longer than
24 h may even be associated with an increased risk of
administrating HES to non-hypovolaemic patients, as this
has been observed in several recent pragmatic trials
[1-3,18,20]. These trials clearly indicate that persistent use
with presumably weak indication has no beneficial effect
or may even be harmful for critically ill patients.
2. We suggest that HES should be limited to acute
volume resuscitation for initial haemodynamic stabili-
sation when hypovolaemia is present. We also suggest
re-assessment of volume status with clearly defined
stopping rules for HES. Total time period of acute
volume resuscitation with HES should not last longer
than 24 h (if volume responsiveness is still present
beyond 24 h, further application of HES is not recom-
mended). (We acknowledge that this suggestion is in
marked contrast to current practice and in conflict
with its licensing or marketing authorisation.)
In the two large pragmatic 6S and CHEST trials [2,3],
patients were resuscitated according to the fluid algorithm
of the participating ICU and the clinicians were allowed to
vary the algorithm from patient to patient (for example
sometimes the physiological variable could be a central
venous pressure below 10 mmHg, which clearly has been
shown to be unrelated to hypovolaemia [36]; in another
patient this could be a heart rate above 90 beats per
minute (bpm)). Although the use of varying algorithms
between participating centres in pragmatic trials may
increase the generalisability of the results, patients are at an
increased risk of receiving overdosed HES in the absence of
a standardised and reliable algorithm for volume resuscita-
tion. Indeed, the lack of goal-directed fluid management
may have caused overinfusion of HES, aggravated haemo-
dilution and potentially increased risk of blood transfusions
in the 6S [3], VISEP [1] and CHEST [2] trials, at least in
part.
3. We suggest using standardised and reliable algo-
rithms of fluid responsiveness and predefined haemo-
dynamic endpoints for acute volume resuscitation in
order to restrict HES to hypovolaemic patients and to
avoid hypervolaemia and any overdosing.
As HES should be limited to hypovolaemic patients,
physicians have to pay more attention at haemodynamic
parameters and specific triggers for volume therapy before
HES infusion starts. However, in the majority of studies
[1-4,7,18,20,21], we could not fully reproduce adequate
indicators for haemodynamic instability, hypovolaemia,
nor increased lactate from published baseline data, respec-
tively. Only three trials [5,6,19] reported data on clinical
signs that reasonably indicate hypovolaemia, thereby
demonstrating that criteria for ‘presumably correct
indication’ were met.
4. We suggest that initiation of HES infusion should
be limited to patients with haemodynamic instability
primarily due to absolute or relative hypovolaemia.
(We acknowledge that this suggestion is in contrast to
current practice and in conflict with its licensing or
marketing authorisation.)
All drug trials need to adhere to the summary of product
characteristics in order to get approval from the authori-
ties. In so far, almost every study considered the maximum
dose in its study protocol apart from two studies [4,6].
However, it has to be acknowledged that the amounts of
study drug reported did not (at least in some trials) include
fluids/ colloids given in the operating room (for example in
[2]). Nevertheless, we found two other studies [1,19] where
in a relevant group of patients maximum daily dose was
exceeded. One study did not provide data on maximal
dose [5].
5. We suggest that the maximum dose of HES should
be complied with.
Hyperoncotic starch solutions with a molecular weight
of 200 kDa are known to result in an increased risk of
renal failure with the need for RRT [1]. Now, the 6S trial
alerts us that even HES solutions with a molecular weight
of 130 kDa may lead to an increased risk of renal failure
and/or need for RRT, when HES was presumably perma-
nently administered in probably ‘non-hypovolaemic’
patients [3]. Contrarily, HES resulted in fewer patients
with ‘risk’ and ‘injury’ according to the risk, injury, failure,
loss, and end-stage renal disease (RIFLE) criteria in the
CHEST trial, although a slightly higher (non-significant)
number of patients received RRT [2]. Also, the CRYST-
MAS study did not find any difference in RIFLE and acute
kidney injury (AKI) criteria [18].
Considering the increased risk of renal failure, exclu-
sion of patients with pre-existing renal failure (oliguria/
anuria) and/or pre-existing RRT is another important
issue regarding adherence to safety issues of product
characteristics. It has to be highlighted, that most of the
study protocols emphasised the exclusion of patients
with pre-existing renal failure and/or RRT prior to ran-
domisation. Under these conditions, good consistency
between study protocol and baseline data was found in
several studies [2,6,7,19,21]. However, we also found
moderate implicit inconsistencies between study proto-
col specifications and published baseline data. Kidney
dysfunction does not necessarily imply renal failure but
rather impaired kidney function. In this respect, ‘acute
kidney injury’ (defined as renal SOFA score of ≥2 or
urine output <500 mL/d) was present in up to 36% of
patients in the 6S trial [3], ‘renal impairment’ (defined
as serum creatinine >3.39 mg/dL) was present in up to
68% of patients in the CRYSTMAS trial [18], and ‘renal
dysfunction’ (defined as urine output ≤0.5 mL/kg/h for
1 h and/or serum creatinine >2 times normal ranges)
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was present in up to 11% of patients in the VISEP trial
[1], respectively.
As the term ‘renal failure’ represents the end-stage of
loss of kidney function, the concept of AKI creates a new
paradigm to encompass the entire spectrum of the syn-
drome from minor changes in markers of renal dysfunc-
tion to requirement for RRT [37]. AKI is defined as any of
the following: increase in serum creatinine by x0.3 mg/dL
within 48 h; or increase in serum creatinine to 1.5 times
baseline; or urine output <0.5 mL/kg/h for 6 h [38]. The
current KDIGO Clinical Practice Guideline for Acute
Kidney Injury [38] even suggests using isotonic crystalloids
rather than colloids (albumin or starches) as initial man-
agement for expansion of intravascular volume in patients
at risk for AKI or with AKI (recommendation level 2,
grade B).
On the other hand, acute oliguria (urine output <0.5 mL/
kg/h for a couple of hours) may be a strong indicator for
acute hypovolaemia, a condition where acute volume
resuscitation with colloids might be indicated.
Taking into account the current guidelines [38] and the
increasing risk of kidney injury after prolonged adminis-
tration of HES, we suggest an expansion of the exclusion
criteria not only to renal failure (as this has been consid-
ered in previous trials in the past) but rather to AKI in
the future.
6. We suggest the following three-step approach:
1. If there is any evidence of pre-existing renal
failure or even AKI, HES should not be given.
2. If there is no evidence of pre-existing renal fail-
ure or AKI but acute oliguria is present, HES might
be indicated in combination with crystalloids, as
oliguria could simply be the consequence of acute
hypovolaemia.
3. If oliguria is unresponsive to acute volume resus-
citation using HES within a time period of maxi-
mum 6 h, HES should be stopped.
The next fundamental problem in the interpretation of
the endpoints of previous studies, in particular need for
RRT, is that standardised definitions for starting RRT have
not yet been used in any of these studies, as no consensus
exists so far. Further, RRT is not a single homogeneous
therapy but rather there are diverse modes of therapy and
various ways of providing RRT that might affect its efficacy
and patient outcome [29-31]. These aspects refers to the
mode (intermittent vs. continuous), timing of RRT initia-
tion and discontinuation, dose, and practice variations
(type of dilution, type of anticoagulation, and so on).
In this respect, we believe, as far as ‘need for RRT’ is
used as a relevant study endpoint, a standardised study
protocol clarifying mode, dose, type of anticoagulation and
rules for starting and stopping of RRT are mandatory.
This may be particularly of interest in multicenter trials
were indication for RRT may differ between centres.
7. We suggest that indication of RRT should be
defined within a study protocol in advance in future
studies, when RTT is used as a relevant study
endpoint.
The final aspect that we would like to address is quality
of data documentation and providing raw data for meta-
analyses. This issue primarily refers to large clinical trials
whose results and conclusions have a major impact on
medical practice, but also on the registration authority
in the EMA or the Food and Drug Administration (FDA).
In smaller studies, standardisation of any study protocol
and adequate data collection is often simple, but sample
size is also insufficient to power for relevant clinical
endpoints. By contrast, large pragmatic trials with several
hundreds or thousands of patients are sufficiently powered
for 90-day mortality, but are highly sophisticated in terms
of valid data collection. This all leads to the double-edged
sword of conducting large well-powered clinical trials. In
this respect, the 6S trial [3] is limited as data of circulatory
parameters (for example, central venous oxygen
saturation) were not registered in up to 67% of patients
during the first 24 h, and also 3-day detailed data on fluid
therapy are missing in up to 19% of patients, respectively.
In terms of raw data, arguments for making raw data
more widely available and sharing data were once more
repeated in a recent editorial in the British Medical Journal
[39] to ensure independent scrutiny, testing of secondary
hypotheses, aiding design of new studies, and simplifying
data acquisition for meta-analyses.
8. We suggest that the best quality of data documen-
tation and adequate follow-up are mandatory in future
trials. Making raw data freely available would enable
both clinicians and scientists to understand and to
interpret study data more appropriately.
Future perspectives - algorithm for clinical management
and safety checklist
The most important question, whether or not HES may be
harmful when it is limited to immediate haemodynamic
stabilisation cannot be answered yet. Currently, no study
is available that sufficiently addresses this question. How-
ever, the recent large-scale trials have nicely demonstrated
that chronic use without proper indication and assessment
may cause harm. This has been the strength of these trials
and can be viewed as an important contribution to safety
in the care of critically ill patients.
In fact, we need additional studies focusing on acute
volume resuscitation and the initial phase of haemody-
namic stabilisation. To overcome the above mentioned
limitations of most of the previous trials, first, we suggest
an algorithm for clinical management emphasising the
strict indication of HES (Figure 1). This algorithm starts
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with the strict identification of patients with hypovolae-
mia. From our point of view, relevant hypovolaemia is
likely if at least one of the following criteria is present:
positive fluid responsiveness, lactate level >3 mmol/L,
central venous oxygen saturation <70%, hypotension/
tachycardia, and/or oliguria. As a second step, acute
volume resuscitation with HES should be limited to a
time interval of less than, in general, 6 h after onset of
shock, to patients without pre-existing renal failure or
AKI (unless oliguria is due to hypovolaemia), and to the
initial phase of volume resuscitation (that should not
last longer than 24 h). We acknowledge that the time
interval of 6 h for starting HES might be tricky if no thera-
peutic intervention at all has been done, or if there are
‘ups and downs’ in the clinical course with a re-occurence
of hypovolaemia. To keep it simple with a clear message
and to avoid any prolonged administration of HES day by
day, however, we suggest that use of HES should be
restricted to the initial phase of volume resuscitation with
a maximum time interval of 24 h.
As a final step, we give a list of suggestions that should
be adequately considered by any planned prospective RCT
in the field of acute volume resuscitation in critically ill
patients in the future (Figure 2).
Figure 1 Algorithm for clinical management considering strict indication.
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Conclusions
As recent RCTs show large heterogeneity in terms of
‘probably correct indication’, the most important question,
whether or not HES may be harmful when it is limited to
acute volume resuscitation cannot be answered yet. We
suggest an algorithm emphasising the strict indication of
HES for patients with hypovolaemia limited to the initial
phase of volume resuscitation. Additionally, we suggest a
safety checklist for future prospective RCTs.
Key messages
• The safety of HES has been questioned in recent
trials, although full adherence to ‘presumably correct
indication’, defined by short time interval from shock
to randomisation, restricted use for initial volume
resuscitation, use of any consistent algorithm for hae-
modynamic stabilisation, reproducible indicators of
hypovolaemia, maximum dose of HES, and exclusion
of patients with pre-existing renal failure or RRT, could
not be found in any of these trials.
• The question, whether or not HES may be harmful
when it is limited to immediate haemodynamic stabili-
sation, cannot be answered yet.
• We suggest an algorithm for clinical management
emphasising the strict indication of HES.
• Further, we suggest a safety checklist for future pro-
spective randomised controlled trials that might be
important in the field of acute volume resuscitation in
critically ill patients.
• The PRAC recommendation is viewed with concern,
since it extrapolates not only from long-term use in
septic patients to acute haemodynamic stabilisation in
this cohort of patients but also to all licensed and not-
licensed (off-label) use of HES.
Additional material
Additional File 1: Characteristics of studies (alphabetical order).
Additional File 2: Probability of ‘presumably correct indication’
(alphabetical order).
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